


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31200271</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2211-0356</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                        <Day>31</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Multiple sclerosis and related disorders</Title>
                <ISOAbbreviation>Mult Scler Relat Disord</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>146-152</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S2211-0348(19)30230-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.msard.2019.05.026</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both natalizumab and fingolimod are highly effective in the treatment of relapsing-remitting MS (RRMS). In the absence of head-to-head trials, some observational studies have compared their efficacy with conflicting results.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the efficacy of natalizumab and fingolimod in a cohort of RRMS patients in an observational, retrospective study.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We included all consecutive RRMS patients who started natalizumab or fingolimod in three MS centres with a follow-up to 24 months and analysed clinical and brain MRI data after propensity score (PS) matching.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">After 1:1 PS-matching, we retained 102 patients in both groups, with similar baseline features. After 24 months, although both drugs resulted highly effective, patients treated with natalizumab had a lower relapse risk (HR 0.59 CI 95% 0.35-1.00, p = 0.048) and higher time to first relapse. MRI-combined-unique-activity was found in 31.8% of natalizumab vs 43.2% of fingolimod treated patients (p = 0.28). We found a higher proportion of patients with confirmed regression of disability (19.2 vs 6.7%, p = 0.03) and 2-year no evidence of disease activity (NEDA-3, 39.0% vs 22.0%, p = 0.04) in the natalizumab group.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both drugs were highly effective in our cohort. Natalizumab proved superior in inducing regression of disability and 2-year-NEDA-3.</AbstractText>
                <CopyrightInformation>Copyright © 2019. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Curti</LastName>
                    <ForeName>Erica</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurosciences Unit, Department of Medicine and Surgery, University of Parma, via Gramsci 14, Parma 43126, Italy. Electronic address: ericacurti1984@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsantes</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurosciences Unit, Department of Medicine and Surgery, University of Parma, via Gramsci 14, Parma 43126, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baldi</LastName>
                    <ForeName>Eleonora</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurology Unit, Department of Neuroscience/Rehabilitation, Azienda Ospedaliera-Universitaria S. Anna, via Moro 8, Cona, Ferrara 44124, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caniatti</LastName>
                    <ForeName>Luisa Maria</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurology Unit, Department of Neuroscience/Rehabilitation, Azienda Ospedaliera-Universitaria S. Anna, via Moro 8, Cona, Ferrara 44124, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferraro</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosciences, Ospedale Civile, Azienda Ospedaliero-Universitaria, via Giardini 1355, Baggiovara, Modena 41126, Italy; Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: diana.ferraro@unimore.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sola</LastName>
                    <ForeName>Patrizia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosciences, Ospedale Civile, Azienda Ospedaliero-Universitaria, via Giardini 1355, Baggiovara, Modena 41126, Italy. Electronic address: p.sola@ausl.mo.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Granella</LastName>
                    <ForeName>Franco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurosciences Unit, Department of Medicine and Surgery, University of Parma, via Gramsci 14, Parma 43126, Italy. Electronic address: franco.granella@unipr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mult Scler Relat Disord</MedlineTA>
            <NlmUniqueID>101580247</NlmUniqueID>
            <ISSNLinking>2211-0348</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Effectiveness</Keyword>
            <Keyword MajorTopicYN="N">Fingolimod</Keyword>
            <Keyword MajorTopicYN="N">Multiple sclerosis</Keyword>
            <Keyword MajorTopicYN="N">Natalizumab</Keyword>
            <Keyword MajorTopicYN="N">Relapsing-remitting</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31200271</ArticleId>
            <ArticleId IdType="pii">S2211-0348(19)30230-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.msard.2019.05.026</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

